Gilead Sciences (GILD) 106.39 $GILD
Final Glance: Biotechnology companies
AP - Thu Sep 11, 5:02PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies were down at the close of trading:
Medivation Eyes Blockbuster As Cancer Drug Gets An OK
at Investor's Business Daily - Thu Sep 11, 4:41PM CDT
Two years ago, biotech Medivation launched its first drug -- an achievement that put it ahead of more than half the biotechs trading on the market. But as of Wednesday afternoon, as far as Wall Street was concerned, it became more than just another...
Stocks Bounce As Nasdaq, S&P 500 Close With Small Gains
at Investor's Business Daily - Thu Sep 11, 3:17PM CDT
The stock market fought back from session lows, closing mostly higher Thursday. The Nasdaq had been down as much as 0.6% in morning trading, but found support around 4560 twice during the session. It closed with a 0.1% gain. The S&P 500 also added...
Stocks Show Modest Losses; Biotechs Pressured Again
at Investor's Business Daily - Thu Sep 11, 1:46PM CDT
Major averages showed modest losses with a little over one hour remaining in Thursday's session. The Nasdaq lost 0.2%, hurt somewhat by a fresh round of selling in biotechland. The Dow Jones industrial average and S&P 500 gave up 0.2% and 0.1%,...
Why Gilead Sciences Stock Is Up 40% in 2014
Todd Campbell, The Motley Fool - Motley Fool - Thu Sep 11, 1:29PM CDT
Gilead Sciences, via Google Maps. Gilead Sciences stock has been on a roll so far this year. Shares in the company's stock have returned 40% this year, outpacing both the S&P 500 index's 10% return and the Nasdaq Biotechnology index's 19%...
Midday Glance: Biotechnology companies
AP - Thu Sep 11, 1:09PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are down at 1 p.m.:
Early Glance: Biotechnology companies
AP - Thu Sep 11, 9:29AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 10 a.m.:
Trading Guidelines for Amgen, Biogen Idec, Gilead, 3 Other Biotechs
at The Street - Thu Sep 11, 9:02AM CDT
Here are some numbers that may help you navigate the volatile and expensive biotech sector.
Jim Cramer's 'Mad Money' Recap: This Is Why Apple Rules
at The Street - Wed Sep 10, 7:10PM CDT
Apple is one of a number of innovators whose shares have risen and rewarded shareholders, Cramer says.
PDL BioPharma Sees Higher-than-Expected Revenues in Q3 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Sep 10, 5:40PM CDT
PDL BioPharma (PDLI) announced that it expects to generate revenues of roughly $165 million in the third quarter of 2014.
Spectrum Pharmaceuticals to Advance Neutropenia Drug - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Sep 10, 4:20PM CDT
Spectrum Pharmaceuticals (SPPI) announced its intention to initiate a phase III study on SPI-2012 next year.
Gilead Sciences Set to Possibly Pullback After Yesterday's Rally of 2.20%
Comtex SmarTrend(R) - Wed Sep 10, 3:36PM CDT
Gilead Sciences (NASDAQ:GILD) traded in a range yesterday that spanned from a low of $105.76 to a high of $108.23. Yesterday, the shares gained 2.2%, which took the trading range above the 3-day high of $106.98 on volume of 11.0 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Watch for Gilead Sciences to Potentially Pullback After Gaining 2.20% Yesterday
Comtex SmarTrend(R) - Wed Sep 10, 3:35PM CDT
Gilead Sciences (NASDAQ:GILD) traded in a range yesterday that spanned from a low of $105.76 to a high of $108.23. Yesterday, the shares gained 2.2%, which took the trading range above the 3-day high of $106.98 on volume of 11.0 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Auxilium Pharmaceuticals to Restructure, Cut Jobs by 30% - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Sep 10, 3:35PM CDT
Auxilium Pharmaceuticals, Inc. (AUXL) announced certain restructuring steps following a comprehensive assessment of Auxilium Pharma's product portfolio in a bid to lower operating costs and drive growth.
Emergent BioSolutions Wins $29M Anthrax Vaccine Deal - Analyst Blog
Maharathi Basu - Zacks Investment Research - Wed Sep 10, 3:30PM CDT
Emergent BioSolutions (EBS) secured a federal contract worth up to $29 million.
Myriad Genetics Posts Encouraging myPath Melanoma Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Sep 10, 2:00PM CDT
Myriad Genetics, Inc. (MYGN) reported favorable results from a pivotal clinical utility study of its myPath Melanoma test.
Stocks Turn Higher After Soft Start; U.S. Silica Jumps
at Investor's Business Daily - Wed Sep 10, 12:25PM CDT
Stocks turned higher in early afternoon trade Wednesday after a soft open. The Nasdaq led the way, rising 0.5%. The Dow Jones industrial average and S&P 500 added 0.1% each. Volume on the NYSE and Nasdaq was tracking 5% to 10% higher than Tuesday's...
Biotech ETFs Slip on Gilead Weakness; Buying Opportunity Now? - ETF News And Commentary
Zacks Equity Research - ZACKS - Wed Sep 10, 11:00AM CDT
A look at biotech ETFs following some weakness in one of the key companies in the space, Gilead (GILD).
Final Glance: Biotechnology companies
AP - Thu Sep 11, 5:02PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies were down at the close of trading:
Medivation Eyes Blockbuster As Cancer Drug Gets An OK
at Investor's Business Daily - Thu Sep 11, 4:41PM CDT
Two years ago, biotech Medivation launched its first drug -- an achievement that put it ahead of more than half the biotechs trading on the market. But as of Wednesday afternoon, as far as Wall Street was concerned, it became more than just another...
Stocks Bounce As Nasdaq, S&P 500 Close With Small Gains
at Investor's Business Daily - Thu Sep 11, 3:17PM CDT
The stock market fought back from session lows, closing mostly higher Thursday. The Nasdaq had been down as much as 0.6% in morning trading, but found support around 4560 twice during the session. It closed with a 0.1% gain. The S&P 500 also added...
Stocks Show Modest Losses; Biotechs Pressured Again
at Investor's Business Daily - Thu Sep 11, 1:46PM CDT
Major averages showed modest losses with a little over one hour remaining in Thursday's session. The Nasdaq lost 0.2%, hurt somewhat by a fresh round of selling in biotechland. The Dow Jones industrial average and S&P 500 gave up 0.2% and 0.1%,...
Why Gilead Sciences Stock Is Up 40% in 2014
Todd Campbell, The Motley Fool - Motley Fool - Thu Sep 11, 1:29PM CDT
Gilead Sciences, via Google Maps. Gilead Sciences stock has been on a roll so far this year. Shares in the company's stock have returned 40% this year, outpacing both the S&P 500 index's 10% return and the Nasdaq Biotechnology index's 19%...
Midday Glance: Biotechnology companies
AP - Thu Sep 11, 1:09PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are down at 1 p.m.:
Early Glance: Biotechnology companies
AP - Thu Sep 11, 9:29AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 10 a.m.:
Trading Guidelines for Amgen, Biogen Idec, Gilead, 3 Other Biotechs
at The Street - Thu Sep 11, 9:02AM CDT
Here are some numbers that may help you navigate the volatile and expensive biotech sector.
Jim Cramer's 'Mad Money' Recap: This Is Why Apple Rules
at The Street - Wed Sep 10, 7:10PM CDT
Apple is one of a number of innovators whose shares have risen and rewarded shareholders, Cramer says.
PDL BioPharma Sees Higher-than-Expected Revenues in Q3 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Sep 10, 5:40PM CDT
PDL BioPharma (PDLI) announced that it expects to generate revenues of roughly $165 million in the third quarter of 2014.
Spectrum Pharmaceuticals to Advance Neutropenia Drug - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Sep 10, 4:20PM CDT
Spectrum Pharmaceuticals (SPPI) announced its intention to initiate a phase III study on SPI-2012 next year.
Gilead Sciences Set to Possibly Pullback After Yesterday's Rally of 2.20%
Comtex SmarTrend(R) - Wed Sep 10, 3:36PM CDT
Gilead Sciences (NASDAQ:GILD) traded in a range yesterday that spanned from a low of $105.76 to a high of $108.23. Yesterday, the shares gained 2.2%, which took the trading range above the 3-day high of $106.98 on volume of 11.0 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Watch for Gilead Sciences to Potentially Pullback After Gaining 2.20% Yesterday
Comtex SmarTrend(R) - Wed Sep 10, 3:35PM CDT
Gilead Sciences (NASDAQ:GILD) traded in a range yesterday that spanned from a low of $105.76 to a high of $108.23. Yesterday, the shares gained 2.2%, which took the trading range above the 3-day high of $106.98 on volume of 11.0 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Auxilium Pharmaceuticals to Restructure, Cut Jobs by 30% - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Sep 10, 3:35PM CDT
Auxilium Pharmaceuticals, Inc. (AUXL) announced certain restructuring steps following a comprehensive assessment of Auxilium Pharma's product portfolio in a bid to lower operating costs and drive growth.
Emergent BioSolutions Wins $29M Anthrax Vaccine Deal - Analyst Blog
Maharathi Basu - Zacks Investment Research - Wed Sep 10, 3:30PM CDT
Emergent BioSolutions (EBS) secured a federal contract worth up to $29 million.
Myriad Genetics Posts Encouraging myPath Melanoma Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Sep 10, 2:00PM CDT
Myriad Genetics, Inc. (MYGN) reported favorable results from a pivotal clinical utility study of its myPath Melanoma test.
Stocks Turn Higher After Soft Start; U.S. Silica Jumps
at Investor's Business Daily - Wed Sep 10, 12:25PM CDT
Stocks turned higher in early afternoon trade Wednesday after a soft open. The Nasdaq led the way, rising 0.5%. The Dow Jones industrial average and S&P 500 added 0.1% each. Volume on the NYSE and Nasdaq was tracking 5% to 10% higher than Tuesday's...
Biotech ETFs Slip on Gilead Weakness; Buying Opportunity Now? - ETF News And Commentary
Zacks Equity Research - ZACKS - Wed Sep 10, 11:00AM CDT
A look at biotech ETFs following some weakness in one of the key companies in the space, Gilead (GILD).
